{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:18:16Z","timestamp":1780532296972,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T00:00:00Z","timestamp":1216339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1007\/s11239-008-0254-6","type":"journal-article","created":{"date-parts":[[2008,7,17]],"date-time":"2008-07-17T16:35:12Z","timestamp":1216312512000},"page":"151-155","source":"Crossref","is-referenced-by-count":13,"title":["Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients"],"prefix":"10.1007","volume":"28","author":[{"given":"Silvia","family":"Riondino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciamaria","family":"Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Torromeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Tanzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio M.","family":"Pulcinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barill\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,7,18]]},"reference":[{"key":"254_CR1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI\u2013CURE study. Lancet 358:527\u2013533. doi: 10.1016\/S0140-6736(01)05701-4","journal-title":"Lancet"},{"key":"254_CR2","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann JT 3rd et al (2002) Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervezntion: a randomized trial. JAMA 288:2411\u20132420. doi: 10.1001\/jama.288.19.2411","journal-title":"JAMA"},{"key":"254_CR3","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1161\/01.CIR.100.15.1667","volume":"100","author":"MJ Quinn","year":"1999","unstructured":"Quinn MJ, Fitzgerald DJ (1999) Ticlopidine and clopidogrel. Circulation 100:1667\u20131672","journal-title":"Circulation"},{"key":"254_CR4","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","volume":"84","author":"P Savi","year":"2000","unstructured":"Savi P, Pereillo JM, Uzabiaga MF et al (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891\u2013896","journal-title":"Thromb Haemost"},{"key":"254_CR5","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","volume":"109","author":"S Matetzky","year":"2004","unstructured":"Matetzky S, Shenkman B, Guetta V et al (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171\u20133175. doi: 10.1161\/01.CIR.0000130846.46168.03","journal-title":"Circulation"},{"key":"254_CR6","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1161\/01.ATV.0000223867.25324.1a","volume":"26","author":"DJ Angiolillo","year":"2006","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2006) Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26:1895\u20131900. doi: 10.1161\/01.ATV.0000223867.25324.1a","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"254_CR7","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","volume":"5","author":"JT Brandt","year":"2007","unstructured":"Brandt JT, Close SL, Iturria SJ et al (2007) Common polymorphisms of CYP2C19 and CYP2C29 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not to prasugrel. J Thromb Haemost 5:2429\u20132436. doi: 10.1111\/j.1538-7836.2007.02775.x","journal-title":"J Thromb Haemost"},{"key":"254_CR8","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","volume":"108","author":"JS Hulot","year":"2006","unstructured":"Hulot JS, Bura A, Villard E et al (2006) Cytochrome P4502C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244\u20132247. doi: 10.1182\/blood-2006-04-013052","journal-title":"Blood"},{"key":"254_CR9","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/PL00012505","volume":"59","author":"N Veillard","year":"2002","unstructured":"Veillard N, Mach F (2002) Statins: the new aspirin? Cell Mol Life Sci 59:1771\u20131756. doi: 10.1007\/PL00012505","journal-title":"Cell Mol Life Sci"},{"key":"254_CR10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","volume":"107","author":"WC Lau","year":"2003","unstructured":"Lau WC, Waskell LA, Watkins PB et al (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug\u2013drug interaction. Circulation 107:32\u201337. doi: 10.1161\/01.CIR.0000047060.60595.CC","journal-title":"Circulation"},{"key":"254_CR11","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/S0195-668X(03)00442-1","volume":"24","author":"H Neubauer","year":"2003","unstructured":"Neubauer H, Gunesdogan B, Hanefeld C et al (2003) Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study. Eur Heart J 24:1744\u20131749. doi: 10.1016\/S0195-668X(03)00442-1","journal-title":"Eur Heart J"},{"key":"254_CR12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/01.CIR.0000124581.18191.15","volume":"109","author":"JV Mitsios","year":"2004","unstructured":"Mitsios JV, Papathanasiou AI, Rodis FI et al (2004) Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5\u00a0weeks in patients with acute coronary syndromes. Circulation 109:1335\u20131338. doi: 10.1161\/01.CIR.0000124581.18191.15","journal-title":"Circulation"},{"key":"254_CR13","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1161\/01.CIR.0000099507.32936.C0","volume":"108","author":"I Muller","year":"2003","unstructured":"Muller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M (2003) Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 108:2195\u20132197. doi: 10.1161\/01.CIR.0000099507.32936.C0","journal-title":"Circulation"},{"key":"254_CR14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0009-9236(98)90023-6","volume":"64","author":"T Kantola","year":"1998","unstructured":"Kantola T, Kivisto KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58\u201365. doi: 10.1016\/S0009-9236(98)90023-6","journal-title":"Clin Pharmacol Ther"},{"key":"254_CR15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","volume":"75","author":"DW Schneck","year":"2004","unstructured":"Schneck DW, Birmingham BK, Zalikowski JA et al (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455\u2013463. doi: 10.1016\/j.clpt.2003.12.014","journal-title":"Clin Pharmacol Ther"},{"key":"254_CR16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11095-005-9371-5","volume":"23","author":"T Sakaeda","year":"2006","unstructured":"Sakaeda T, Fujino H, Komoto M et al (2006) Effects of acid and lactone forms of eight HMG\u2013CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 23:506\u2013512. doi: 10.1007\/s11095-005-9371-5","journal-title":"Pharm Res"},{"key":"254_CR17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ahj.2004.03.028","volume":"148","author":"DL Bhatt","year":"2004","unstructured":"Bhatt DL, Topol EJ, CHARISMA Executive Committee (2004) Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 148:263\u2013268. doi: 10.1016\/j.ahj.2004.03.028","journal-title":"Am Heart J"},{"key":"254_CR18","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2165\/00003088-200342120-00004","volume":"42","author":"C Cerletti","year":"2003","unstructured":"Cerletti C, Dell\u2019Elba G, Manarini S et al (2003) Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 42:1059\u20131070. doi: 10.2165\/00003088-200342120-00004","journal-title":"Clin Pharmacokinet"},{"key":"254_CR19","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","volume":"14","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol 14:1505\u20131516. doi: 10.1016\/j.jacc.2006.11.044","journal-title":"J Am Coll Cardiol"},{"key":"254_CR20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.blre.2004.05.002","volume":"19","author":"P Harrison","year":"2005","unstructured":"Harrison P (2005) Platelet function analysis. Blood Rev 19:111\u2013123. doi: 10.1016\/j.blre.2004.05.002","journal-title":"Blood Rev"},{"key":"254_CR21","first-page":"291","volume-title":"Platelets","author":"MA Refaai","year":"2004","unstructured":"Refaai MA, Laposata M (2004) Platelet aggregation. In: Michelson AD (ed) Platelets. Academic, San Diego, pp 291\u2013296"},{"key":"254_CR22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jacc.2003.08.062","volume":"43","author":"FM Pulcinelli","year":"2004","unstructured":"Pulcinelli FM, Pignatelli P, Celestini A et al (2004) Inhibition of platelet aggregation by aspirin progressively decreases in long term-treated patients. J Am Coll Cardiol 43:979\u2013984. doi: 10.1016\/j.jacc.2003.08.062","journal-title":"J Am Coll Cardiol"},{"key":"254_CR23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jacc.2005.02.092","volume":"46","author":"B Labarthe","year":"2005","unstructured":"Labarthe B, Theroux P, Angioi M et al (2005) Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 46:638\u2013645. doi: 10.1016\/j.jacc.2005.02.092","journal-title":"J Am Coll Cardiol"},{"key":"254_CR24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2362.2005.01522.x","volume":"35","author":"F Mach","year":"2005","unstructured":"Mach F, Senouf D, Fontana P et al (2005) Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 35:476\u2013481. doi: 10.1111\/j.1365-2362.2005.01522.x","journal-title":"Eur J Clin Invest"},{"key":"254_CR25","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","volume":"107","author":"PA Gurbel","year":"2003","unstructured":"Gurbel PA, Bliden KP, Hiatt BL et al (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908\u20132913. doi: 10.1161\/01.CIR.0000072771.11429.83","journal-title":"Circulation"},{"key":"254_CR26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1160\/TH06-09-0491","volume":"96","author":"A Pampuch","year":"2006","unstructured":"Pampuch A, Cerletti C, de Gaetano G (2006) Comparison of VASP-phosphorylation assay to light transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 96:767\u2013773","journal-title":"Thromb Haemost"},{"key":"254_CR27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","volume":"3","author":"B Aleil","year":"2005","unstructured":"Aleil B, Ravanat C, Cazenave JP et al (2005) Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3:85\u201392. doi: 10.1111\/j.1538-7836.2004.01063.x","journal-title":"J Thromb Haemost"},{"key":"254_CR28","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.jacc.2005.07.056","volume":"46","author":"PA Gurbel","year":"2005","unstructured":"Gurbel PA, Bliden KP, Samara W et al (2005) Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 46:1827\u20131832. doi: 10.1016\/j.jacc.2005.07.056","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-008-0254-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-008-0254-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-008-0254-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T11:01:39Z","timestamp":1559386899000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-008-0254-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,18]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["254"],"URL":"https:\/\/doi.org\/10.1007\/s11239-008-0254-6","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,18]]}}}